Parmax Pharma Limited
Latest filings
- Annual Report FY2025-26 and Notice of 32nd AGM on Sept 29, 2026 · Board & Shareholder Meetings
- Parmax Pharma 32nd AGM on Sept 29, 2026 via video conferencing · Board & Shareholder Meetings
- Parmax Pharma allots shares and warrants on preferential basis · Fund Raising
- New promoter group takes over Parmax Pharma with 30.80 percent stake acquisition · Ownership Changes
- Post Offer Advertisement published for Parmax Pharma open offer · Compliance
- In-Principle Approval for Preferential Issue of Shares and Warrants · Fund Raising
- Quarterly results published in English and Gujarati newspapers · Compliance
- Promoters exit Parmax Pharma completely with 30.81 percent stake sale via off-market deal · Ownership Changes
- Non-promoter group acquires 58% stake in Parmax Pharma via off-market SPA · Ownership Changes
- Parmax Pharma: Acquirer group buys 11.52 lakh shares, stake crosses 50 percent · Ownership Changes
- Board meeting on Aug 14, 2026 to consider Q1 FY27 results · Results
- Open Offer for 26 percent stake in Parmax Pharma at Rs 42.80 per share · Compliance
- IDC recommendation on Parmax open offer published in newspapers · Compliance
- Open Offer at Rs 42.80 launched for 26% stake in Parmax Pharma · Strategic Transactions
- Parmax Pharma files Q1 FY27 dematerialisation compliance certificate · Compliance
- Parmax Pharma EGM: All 4 resolutions pass, preferential issues approved · Board & Shareholder Meetings
- Amendments to MOA and AOA, Authorized Capital raised to Rs. 10 Crore · Corporate Actions
- Parmax Pharma EGM: All 4 resolutions passed with 100 percent approval · Board & Shareholder Meetings
- Parmax Pharma EGM clears capital raise via preferential shares and warrants · Board & Shareholder Meetings
- Trading window closed from July 1 ahead of Q1 results · Compliance
- Corrigendum to EGM notice published in newspapers · Compliance
- Corrigendum to EGM Notice for Preferential Issue of Warrants · Management Changes
- Non-promoter Pradeep Gosalia exits 8.02% stake in Parmax Pharma · Ownership Changes
- Draft Letter of Offer filed with BSE for Parmax Pharma public shareholders · Strategic Transactions
- PAC buys 2.49 lakh shares of Parmax Pharma during open offer period · Strategic Transactions
- SAST disclosure from promoters Dhiren Shah, Sunil Shah and PACs · Ownership Changes
- Open Offer for 26% stake in Parmax Pharma from public shareholders · Strategic Transactions
- Notice of EGM scheduled to be held on July 02, 2026 · Board & Shareholder Meetings
- Share purchase agreement and Public Announcement · Strategic Transactions
- Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulation 3(1) And Regulation 4 Read with Regulation 13, Regulation 14 And Regulation .... · Strategic Transactions
- Issue of Shares and Warrants on Preferential basis pursuant to SEBI ICDR Regulations · Fund Raising
- Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/06/2026 ,inter alia, to consider and approve Fund raising · Fund Raising
- Results for Financial Results for Quarter and Financial Year ended March 31, 2026 · Results
- Reschedule of Boar Meeting and Outcome of Board Meeting · Results
- Proceedings of EGM held on May 27, 2026 · Board & Shareholder Meetings
- Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2026 ,inter alia, to consider and approve audited financial results for .... · Results
- Scrutinizer Report · Compliance
- Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve audited financial results of .... · Results
- Notice of Extra-ordinary General Meeting of the Company scheduled to be held on May 27, 2026 · Board & Shareholder Meetings
- Re-appointment of Mr. Umang Gosalia as a Managing Director of the Company · Management Changes
- <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
- RTA Compliance certificate for Quarter ended March 31, 2026 · Compliance
- Closure of trading window · Compliance
- Appointment of Ms. Bhakti Aghera as a Company Secretary · Management Changes
- Unaudited Financial results for quarter and Nine months ended 31.12.2025 · Results
- Outcome of Board meeting for Financial Results · Results
- Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Unaudited Financial results for .... · Results
- RTA Certificate under regulation 74(5) of SEBI DP Regulations for quarter ended December 31, 2025 · Compliance
- Closure of trading window · Compliance
- The Board meeting for approval of Financial statements was rescheduled initially on November 15, 2025 and thenafter on today i.e. November 17, 2025. The Board has approved the unaudited .... · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹12 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from Parmax Pharma Limited's filed financials and exchange disclosures
What does Parmax Pharma Limited do?
Parmax Pharma Limited is a Pharmaceuticals & Biotechnology company listed on BSE.
Is Parmax Pharma Limited profitable?
No. Over the trailing twelve months Parmax Pharma Limited reported a net loss of ₹4 Cr on revenue of ₹12 Cr.
Does Parmax Pharma Limited pay a dividend?
Not in the latest reported year — Parmax Pharma Limited's dividend payout for FY26 was nil.
Is Parmax Pharma Limited debt-free?
Effectively yes. Debt stands at -1.87× equity.
Is Parmax Pharma Limited expensive compared with its peers?
On trailing P/E, Parmax Pharma Limited ranks 33 of 170 in Pharmaceuticals — cheaper than 81% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.
How much does the Parmax Pharma Limited share price move in a day?
On a typical session Parmax Pharma Limited moves 2.00% — that is the median absolute close-to-close move across its last 250 trading days. Announcement days are routinely larger.
Where can I track Parmax Pharma Limited's announcements?
Every NSE and BSE filing by Parmax Pharma Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.